Tetra Bio-Pharma Inc. has signed an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 (onternabez) as a combination product with Qifenda (favipiravir) 400 mg, a commercial-stage broad-spectrum antiviral drug.
Biovaxys Technology Corp. has announced that Millipore-Sigma, the contract manufacturer for its preclinical viral vaccine program, has completed the bioproduction and batch release endotoxin screening of BVX-1021, the company's vaccine for SARS-CoV, which is being used in the collaboration with The Ohio State University (OSU) to develop a pan-sarbecovirus vaccine.
Immunoprecise Antibodies Ltd.'s Polytope TATX-03 antibody combination therapy has been shown to neutralize SARS-CoV-2 variants of concern, including the omicron BA.5 subvariant, in an authentic virus assay.
Stemcyte Inc. has received IND approval from the FDA for a phase II trial using umbilical cord blood stem cell therapy for post-COVID syndrome, or long COVID.